Arrowhead Pharmaceuticals, Inc.
Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin

Last updated:

Abstract:

The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.

Status:
Application
Type:

Utility

Filling date:

31 May 2019

Issue date:

19 Sep 2019